Last updated on November 2017

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease.


Brief description of study

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease.

Detailed Study Description

The purpose of this study is to see if the study drug, suvorexant, is safe and effective in treating symptoms of insomnia in people with Parkinson's Disease. It is anticipated that a total of 20 subjects, 30 to 80 years of age, with Parkinson's Disease and symptoms of insomnia will participate in the study at this site. Subjects will undergo a polysomnogram as part of the study. Active drug will be suvorexant 10 mg orally at bed time with an optional up-titration to 15 mg orally at bedtime after 2 weeks.

Clinical Study Identifier: TX8849

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

EvergreenHealth Research Program

EvergreenHealth Research Program
Kirkland, WA USA
  Connect »